Subscribe
istock-652532896_filograph
filograph / iStockphoto.com
19 September 2018Americas

CRISPR Therapeutics unites with ViaCyte to treat diabetes

Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14 December 2017   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.
Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
13 November 2018   Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

More on this story

Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14 December 2017   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.
Americas
CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
13 November 2018   Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.

More on this story

Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14 December 2017   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.
Americas
CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
13 November 2018   Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool